A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™

Trial Profile

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms ENGINE
  • Sponsors Denovo Biopharma
  • Most Recent Events

    • 24 Oct 2017 According to a Denovo Biopharma media release, US FDA has granted IND clearance to proceed for this trial and it is recently approved by Food and Drug Administration (CFDA).
    • 28 Aug 2017 Status changed from planning to not yet recruiting.
    • 20 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top